Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.

doi:10.1007/s00401-011-0938-4

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.

Acta neuropathologica - 1 Jun 2012

Hegi Monika E, Janzer Robert-Charles, Lambiv Wanyu L, Gorlia Thierry, Kouwenhoven Mathilde C M, Hartmann Christian, von Deimling Andreas, Martinet Danielle, Besuchet Schmutz Nathalie, Diserens Annie-Claire, Hamou Marie-France, Bady Pierre, Weller Michael, van den Bent Martin J, Mason Warren P, Mirimanoff René-Olivier, Stupp Roger, Mokhtari Karima, Wesseling Pieter

Abstract excerpt

Glioblastoma (GBM) is a morphologically heterogeneous tumor type with a median survival of only 15 months in clinical trial populations. However, survival varies greatly among patients. As part of a central pathology review, we addressed the question if patients with GBM displaying distinct morphologic features respond differently to combined chemo-radiotherapy with temozolomide. Morphologic features were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemoradiotherapy

Share to Clinical Trials, Phase III as Topic

Share to Dacarbazine

Share to Glioblastoma

Share to Oligodendroglioma

Share to Survival Analysis

Share to Temozolomide

Source

Open in PubMed

Identifiers

PMID: 22249618
DOI: 10.1007/s00401-011-0938-4

Genes

MGMT
EGFR
IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.PMID 22249618Read ↗

Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcomeSemantic proximity Read ↗

Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics.Semantic proximity Read ↗

Glioblastoma: Biology, Genetics, and BehaviorSemantic proximity Read ↗

Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age.Semantic proximity Read ↗

Glioblastomas with oligodendroglial component have the same clinical phenotype as classical glioblastomas.Semantic proximity Read ↗

Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.Semantic proximity Read ↗

Current Opinion on Molecular Characterization for GBM Classification in Guiding Clinical Diagnosis, Prognosis, and TherapySemantic proximity Read ↗

Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis.Semantic proximity Read ↗

Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumorsSemantic proximity Read ↗

A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.Semantic proximity Read ↗

Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.Semantic proximity Read ↗

GLIOBLASTOMA MULTIFORME: A META-ANALYSIS OF DRIVER GENES, CURRENT DIAGNOSIS, AND TUMOR HETEROGENEITYSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.